IART Cremona,
|
|
- Elisabeth Davis
- 5 years ago
- Views:
Transcription
1 IART Cremona, Quale spazio per la terapia biologica? Nicola Fazio, M.D., Ph. D. Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology Milan, Italy
2 SUNITINIB SSA Endothelial cell Pericytes PDGFR SSTRs NET tumor cells VEGFR IGF1-R RAS PLC PI3K Jak/STAT RAF PKC Akt EVEROLIMUS MEK mtorc-1 ERK
3 Therapies for patients with advanced NET SSA Everolimus / Sunitinib Chemotherapy PRRT Liver-directed treatments Primary tumor removal
4 Therapies for patients with advanced NETs FDA/EMA Approved Sunitinib Everolimus in pnet Lanreotide in GEP Telotristat in refractory carcinoid syndrome diarrhea STZ in pnet Octreotide IFN in carcinoid syndrome Lanreotide in carcinoid syndrome Octreotide in midgut Everolimus in non functioning Lung and GI PRRT in GEP NET TMZ Oxaliplatin Not FDA/EMA approved Liver-directed: TACE/TAE TARF/TARE Bevacizumab Pasireotide STZ: streptozotocin; TMZ: Temozolomide; IFN: Interferon; GEP: Gastroenteropancreatic; TACE: Trans-Arterial-Chemoembolization; TAE: Trans-arterial-embolization; TARE: Trans-arterial radioembolization
5 NET guidelines from several different scientific societes Oncological scientific societes NEN scientific societes Italian NEN guidelines
6 Advanced pancreatic NET
7 Phase III trial-related evidence in pnet trial Presented/pub lished therapy PFS exp. arm PFS PLB arm setting CLARINET Caplin, NEJM 2014 LAN A vs. PLB Not reached 12 mo Well-diff RADIANT-3 NCT Yao, NEJM 2011 Raymond, NEJM 2011 EVE vs. PLB 11.4 mo 5.4 mo Well-diff SUN vs. PLB 11.4 mo 5.5 mo Well-diff
8 Everolimus Placebo 11.4 m 5.4 m Yao, NEJM 2011 Sunitinib Placebo 11.4 m 5.5 m Early stop due to significant difference in deaths, SAEs, and PFS 340 pts planned 171 enrolled Raymond, NEJM 2011
9
10 2006 Phase I 2008 Phase II 2011 Phase III
11 Sunitinib in NET: preclinical and phase I experience Preclinical In the RIP1-Tag2 transgenic mouse model of pancreatic islet cell carcinoma, sunitinib: reduced tumor burden and increased survival reduced endothelial cell population (VEGFR inhibition) reduced pericyte coverage (PDGFR inhibition) Phase I A study of sunitinib in solid tumors included 4 patients with non-pancreatic NET, inducing: 1 confirmed PR (rectal NET with bulky peritoneal metastases; he received sunitinib 75 mg/day 4/2 weekly) 1 minor response/sd Pietras K & Hanahan D. J Clin Oncol 2005;23:939 52; Yao V, et al. EORTC-NCI-AACR, Prague, 2007, Abstract 78 Faivre S, et al. J Clin Oncol 2006;24:25 35;
12 Phase II trial 50 mg/day 4/6 weeks prior SSA 50% pts with NET (small cell excluded) 65 pts With pnet 40 pts with NET from other origin 46 Non functioning 19 functioning prior SSA 30% Kulke et al., JCO 2008
13 Phase II trial PR m TTP Pancreatic 16.7 % 7.7 mo Non pancreatic 2.4 % 10.2 mo Kulke et al., JCO 2008
14 Phase III, Randomized, Double-Blind Study of Sunitinib vs. Placebo in Patients with Advanced, Progressive, Well-Differentiated Pancreatic Endocrine Tumors Accrual goal = 340 pts Primary endpoint: PFS R A N D. Secondary endpoints: OS, ORR, TTR, duration of response, safety, patient-reported outcomes 1:1 Arm A Sunitinib 37.5 mg/day orally, continuous daily dosing (CDD)* Arm B Placebo Crossover Progression of disease Open-label sunitinib protocol (NCT or NCT )
15 Non functioning, well differentiated, advanced pancreatic NET Lanreotide or CLARINET trial Octreotide Everolimus or Sunitinib RADIANT-3 trial A trial 1 2
16 Metastatic pannet: Everolimus Sunitinib or Sunitinib Everolimus? Criterion Regulatory features Evidence Biological background Clinical wisdom
17 Everolimus Investigation in NETs RADIANT (RAD001 in Advanced Neuroendocrine Tumors) Phase III Phase II RADIANT-3 RADIANT-4 RADIANT-2 RADIANT EVE+OCT RAMSETE LUNA EVE+OCT 1 ST Line ITMO
18 Targ Oncol DOI /s REVIEW ARTICLE Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors Diana Martins 1 &Francesca Spada 1 &Ioana Lambrescu 1 &Manila Rubino 1 & ChiaraCella 1 &Bianca Gibelli 2 &ChiaraGrana 3 &Dario Ribero 4 &Emilio Ber tani 4 & Davide Ravizza 5 &Guido Bonomo 6 &Luigi Funicelli 7 &EleonoraPisa 8 &Dario Zer ini 9 & Nicola Fazio 1 &IEO ENETS Center of Excellence for GEP NETs # Springer International Publishing Switzerland 2017 Abstract Neuroendocrine tumors (NETs) represent a large and heterogeneous group of malignancies with various bio- accurate biomarkers for predicting tumor response and effica- No validate predictive biomarker for sunitinib and everolimus so far * Nicola Fazio nicola.fazio@ieo.it logical and clinical characteristics, depending on the site of origin and the grade of tumor proliferation. In NETs, as in other cancer types, molecularly targeted therapies have radically changed the therapeutic landscape. Recently two targeted agents, the mammalian target of rapamycin inhibitor everolimus and the tyrosine kinase inhibitor sunitinib, have both demonstrated significantly prolonged progression free survival in patients with advanced pancreatic NETs. Despite these important therapeutic developments, there are still significant limitationsto theuseof theseagentsdueto thelack of cy of therapy. In this review, we provide an overview of the current clinical data for the evaluation of predictive factors of response to/efficacy of everolimus and sunitinib in advanced pancreatic NETs. Surrogate indicators discussed include circulating and tissue markers, as well as non-invasive imaging techniques. Key Points Everolimus and sunitinib are widely investigated targeted cancer therapies, and they are both globally approved by regulatory authorities for the treatment of pancreatic NETs Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Instituteof Oncology, IEO, viaripamonti, 435 Milan, Italy Division of Otolaryngology-Head and Neck Surgery, European Institute of Oncology, IEO, Milan, Italy Division of Nuclear Medicine, European Institute of Oncology, IEO, Milan, Italy Division of Hepatobiliopancreatic Surgery, European Institute of Oncology, IEO, Milan, Italy The establishment of predictive markers of response to everolimus and sunitinib in NETs is of extreme importance for their efficient use. Most efforts to define predictive biomarkers have failed, with the exception of chromogranin-a and neuron-specific enolase for advanced pancreatic NETs treated with everolimus. Martins et al., Targeted Oncol 2017
19 Dual modulation of Mcl-1 and mtor by sunitinib determines the response of cancer cells Comparison of patient samples prior and post sunitinib treatment suggests that increasing Mcl-1 levels and mtorc1 activity correlates with resistance to sunitinib in patients Suni4nib ERK GSK3b Combinatorial treatment Mcl- 1 inhibitors Mcl- 1 mtor Rapalogs/ Starva4on Sensi4za4on Elgendy et al., JCI 2016
20 Everolimus > Sunitinib vs. Sunitinib > Everolimus in renal cancer RECORD-3 trial
21 Everolimus > Sunitinib was not non-inferior to the opposite sequence
22 An Italian real world analysis of sunitinib in pannet 73 pts with advanced pnet (71% >/= 3 lines) 82% with prior Everolimus PR 19 % SD 53 % PFS 11 mo mos 36 mo Confirmed activity and toxicity profile even beyond Everolimus and/or PRRT Panzuto et al., Pancreatology Nov 2017
23 CI=confidence interval; mpfs=median progression-free survival; PFS=progression-free survival; pnets=pancreatic neuroendocrine tumors 1: Trial ORRwas Profile Sunitinib in pannet: data about first-line and cytoreductive effect 24.5% (95% CI, ) according to the investigator assessment (Table 2). 123 patients screened Table 2: Best Observed Response by RECIST, Assessed by Investigators 106 patients enrolled Previously Treatment-naïve Treated 1 txt-naïve patients treated 45 previously treated n=61 patients treated n=45 Best overall response, n (%) 3 txt-naïve Complete patients discontinued response txt 39 previously 2 treated (3.3) patients discontinued 1 txt(2.2) 3 (2.8) 26 Objective progression/relapse 23 Objective progression/relapse Partial response 11 (18.0) 12 (26.7) 23 (21.7) 6 Adverse events 8 Adverse events 4 Refusal Stable of txt disease for reason other than AE 1 Refusal 40 of txt (65.6) for reason other than AE 29 (64.4) 69 (65.1) 2 Global Progressive health deterioration disease 2 Global health 7 (11.5) deterioration 2 (4.4) 9 (8.5) 1 Death Indeterminate 1 Death 1 (1.6) 1 (2.2) 2 (1.9) 4 Other 4 Other ORR,* n (%) 13 (21.3) 13 (28.9) 26 (24.5) 95% CI fficacy * Complete analysis: response 61 txt-naïve + partial patients response. 45 previously treated patients * Complete response + partial response. Raymond et al., ENETS 2017, Poster session afety CI=confidence analysis: 61 interval; txt-naïve ORR=objective patients response 45 rate; previously RECIST=Response treated patients Evaluation Criteria in Solid Tumors CI=confidence interval; ORR=objective response rate; pnet=pancreatic neuroendocrine tumor; RECIST=Response Evaluation Criteria in Manuscript under review vent; txt=treatment RECIST-based Table 2: Best Observed Response Based on Independent Third-Party Radiology According to Choi Criteria in Treatment-Naïve and Previously Treated Patients With pnets Choi-based Total N=106 Best overall response, n (%) Vomiting 8 (13.1) 1 (1.6) 1 Asthenia 10 (16.4) 0 (0.0) 7 Abdominal pain upper 5 (8.2) 1 (1.6) 7 ALT increased 2 (3.3) 1 (1.6) 9 AST increased 4 (6.6) 1 (1.6) 7 Constipation 3 (4.9) 0 (0.0) 7 Dizziness 3 (4.9) 0 (0.0) 7 Hypophosphatemia 2 (3.3) 2 (3.3) 7 Myalgia 2 (3.3) 0 (0.0) 7 Treatment-Naïve n=61 Previously Treated n=45 Adverse events are listed by highest to lowest % for Total/All Grades patie * Adverse events reported by 15% in any treatment group per MedDRA ALT=alanine aminotransferase; AST=aspartate aminotransferase; MedDR Complete response 0 1 (2.2) CONCLUSIONS Partial response 32 (52.5) 24 (53.3) n The study confirmed sunitinib is an efficac Stable disease n Median 12 (19.7) PFS of 13.2 months 17 (37.8) (95% CI, 10. Progressive disease ) 9 (14.8) observed in this 2 (4.4) phase IV trial Indeterminate phase III trial of sunitinib in pnets and co 8 (13.1) 1 (2.2) ORR,* n (%) n OS data 32 (52.5) were not mature 25 at (55.6) the time of t 95% CI n AEs were consistent with the known safet Solid Tumors in progressive, locally advanced and/or m unresectable pnets. TTP (mo) TTP (mo)
24 Metastatic indolent SSTR-2 + pancreatic NET TAE / TACE / TARE Liver surgery RT Primary tumor removal SSA Everolimus or Sunitinib Sunitinib or Everolimus PRRT Chemotherapy Clinical trials
25 Advanced pannets 2016 ENETS guidelines Minimal consensus statement: Everolimus or sunitinib are generally recommended after failure of SSA or chemotherapy in pancreatic NET. Everolimus and sunitinib.. can be considered a first line therapy, especially if SSA is not an option, and if systemic chemotherapy is not clinically required, not feasible or not tolerated. Pavel et al., Neuroendocrinology Jan 2016
26 Advanced well differentiated pannet According to ENETS guidelines SSA Chemotherapy Everolimus or Sunitinib Sunitinib or Everolimus PRRT
27 Everolimus in pannets: Prior chemotherapy Prior therapy EVE PBO Surgery n.r. n.r. Radiotherapy 23 % 20 % Chemotherapy 50 % 50 % SSA 49 % 50 % Yao et al., NEJM 2011
28 Sunitinib in pannets: Prior chemotherapy Concomitant SSA treatment, n (%) of patients Started prior to study and continued Started during study 17 (20.5) 15 (18.1) 2 (2.4) 18 (22.0) 12 (14.6) 6 (7.3) Raymond et al., NEJM 2011
29 Advanced pancreatic NET G3
30 Overall survival of 136 patients with GEP NEC according to subtype Type A = well diff. + Ki % Type B = poorly diff. + Ki % Type C = poorly diff. + Ki-67 > 55% Milione et al., Neuroendocrinology Mar 2016
31 Neuroendocrinology (DOI: / ) Table 1. Clinico-pathological features of 136 patients with NEC ALL Type A Type B Type C Total Gender Men Women Tumor site Esophagus Stomach Duodenum Ileum cecum appendix Colon rectum Pancreas Gallbladder Mitotic count /10HPF < CD117 Negative Positive Missing pannec = 24% of the total population 30% of pnec were NET G3 (or type A) Pancreas as the most frequent primary site among NET G3 MMRd Angio-invasion Absent Present Missing Milione et al., Neuroendocrinology Mar 2016
32 GEP NEC heterogeneity: possible clinical implications WD = well differentiated; PD = poorly differentiated
33 Everolimus in pannet G3 15 pts with pannet (all well/moderately differentiated) and 20-55% Ki-67 All pre-treated, mostly with chemotherapy mpfs = 6 mo mos = 28 mo Panzuto et al., Pancreas 2017
34 Sunitinib in NET/NEC G3 Clinical and biomarker evaluations of sunitinib in patients (pts) with advanced well-differentiated grade 3 (G3) and poorly differentiated neuroendocrine neoplasms (PD-NEN). Dreyer et al., POSTER ASCO GI /26 pts (23%) had SD or PR 3 pts were NET G3
35 Pancreatic NET G3 IEO patient with liver mets from moderately differentiated pancreatic NET, Ki67 40% Resistant to platinum-based chemotherapy 1 month of Sunitinib 37.5 mg/d
36 GETNE-1206 (SEQTOR): Phase III Study in Patients With Advanced GETNE pnet1206 (SEQTOR) phase III trial in patients with advanced pannets Compare efficacy and safety of everolimus followed by chemotherapy with STZ + 5-FU upon progression, or the enrolling reverse sequence (chemotherapy with STZ + 5-FU followed by everolimus upon progression) Arm A: Everolimus Everolimus Progression Arm B: STZ + 5-FU STZ + 5-FU Primary end point: rate of second PFS at 84 weeks of treatment Unpublished data. Clinicaltrials.gov ID, NCT
37 Therapies sequencing in non-functioning metastatic midgut NET: evidence 1 2
38 Metastatic SSTR-2 positive midgut NET Primary tumor removal TAE / TACE / TARE Liver surgery RT SSA PRRT Everolimus Clinical trials
39 Sequence of therapies in refractory carcinoid syndrome SSA dose/schedule Locoregional PRRT IFN adjustment treatments EVE diarrhea
40 New TKIs
41 Novel TKIs in GEP NETs Phase III Phase III Phase III
42 CDK 4/6 inhibitors
43 CDK 4/6 inhibition in NET: preclinical studies with RIBOCICLIB and PALBOCICLIB Neuroendocrinology (DOI: / ) 2017 S. CDK4/6 controls cell cycle progression from G1 to S phase by regulating the activity of Rb Prada et al, Neuroendocrinology 2016 Tang L. et al., Clin Cancer Res 2012 Fig. 1. Proposed and simplified mode of action of the CDK4/6 inhibitor LEE01
44 Immune checkpoint inhibitors
45 PDR001 in GEP and Lung NET/NEC Phase II multi-cohort international study PDR001 binds to PD-1 so blocking both PD-L1 and PD-L2 Well differentiated: GI cohort (n=30) Pancreatic cohort (n=30) Thoracic cohort (n=30) Poorly differentiated: GEP cohort (n=20)
46 A multicohort phase II study of durvalumab plus tremelimumab for the treatment of patients (PTS) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic (GEP) or lung origin (the DUNE trial-getne1601-). Single-arm Phase II 126 pts Well differentiated: GI cohort (n=30) Pancreatic cohort (n=30) Thoracic cohort (n=30) Durvalumab (anti-pd-l1) Poorly differentiated: GEP cohort (n=20) Tremelimumab (anti-ctla-4)
47 European Institute of Oncology, IEO, Milan, Italy ENETS Center of Excellence for GEP NETs IEO NET MDT
Ongoing and future clinical investigation in GEP NENs
ESMO PRECEPTORSHIP PROGRAMME Multidisciplinary management, standards of care and future perspectives Lugano, Switzerland 13-14 April 2018 CHAIR: Nicola Fazio, Italy George Pentheroudakis, Greece Ongoing
More informationTRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS
TRACTAMENT ONCOLÒGIC DELS TUMORS NEUROENDOCRINS METASTÀSICS Jaume Capdevila Unitat de Tumors GI i Endocrins Hospital Universitari Vall d Hebron Barcelona Experts, acollidors i solidaris OUTLINE BACKGROUND
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationCutting Edge Treatment of Neuroendocrine Tumors
Cutting Edge Treatment of Neuroendocrine Tumors Daneng Li, MD Assistant Clinical Professor Department of Medical Oncology & Therapeutics Research City of Hope Click to edit Master Presentation Date DISCLOSURE
More informationMEDICAL MANAGEMENT OF METASTATIC GEP-NET
MEDICAL MANAGEMENT OF METASTATIC GEP-NET Jeremy Kortmansky, MD Associate Professor of Clinical Medicine Yale Cancer Center DISCLOSURES: NONE Introduction Gastrointestinal and pancreatic neuroendocrine
More informationReview of Gastrointestinal Carcinoid Tumors: Latest Therapies
Review of Gastrointestinal Carcinoid Tumors: Latest Therapies Arvind Dasari, MD, MS Department of Gastrointestinal Medical Oncology The University of Texas MD Anderson Cancer Center Houston, TX, USA Neuroendocrine
More informationJaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology
Jaume Capdevila, MD GI and Endocrine Tumor Unit Vall d Hebron University Hospital Developmental Therapeutics Unit Vall d Hebron Institute of Oncology OUTLINE Molecular Rationale for the use of SSAs in
More informationNET εντέρου Τι νεότερο/ Νέες μελέτες. Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ
NET εντέρου Τι νεότερο/ Νέες μελέτες Μαντώ Νικολαΐδη παθολόγος-ογκολόγος ΜΗΤΕΡΑ NET: A Diverse Group of Malignancies 1-3 Wide spectrum of malignancies arising in neuroendocrine cells throughout the body
More informationBackground. Capdevila J, et al. Ann Oncol. 2018;29(Suppl 8): Abstract 1307O. 1. Dasari A, et al. JAMA Oncol. 2017;3(10):
Efficacy of Lenvatinib in Patients With Advanced Pancreatic (pannets) and Gastrointestinal (ginets) WHO Grade 1/2 (G1/G2) Neuroendocrine Tumors: Results of the International Phase II TALENT Trial (GETNE
More informationNuevas alternativas en el manejo de TNE avanzados
Nuevas alternativas en el manejo de TNE avanzados Jaume Capdevila Hospital Universitari Vall d Hebron Barcelona Coordinación científica: Dr. Fernando Rivera Hospital Universitario Marqués de Valdecilla,
More informationGEP NET: algoritmo terapeutico. Dottor Nicola Fazio
GEP NET: algoritmo terapeutico Dottor Nicola Fazio Basi per il trattamento Caratteristiche del paziente Caratteristiche del tumore P.S., sindrome, comorbidità Differenziazione, Ki-67 Imaging morfologico
More information2015: Year in Review Results of Recent Trials
2015: Year in Review Results of Recent Trials Pamela L. Kunz, MD Assistant Professor of Medicine / GI Oncology Director, Stanford NET Program Stanford University School of Medicine Disclosures Research
More informationNET del pancreas ben differenziato: la terapia oncologica. Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia
NET del pancreas ben differenziato: la terapia oncologica Alfredo Berru: Università degli Studi di Brescia Azienda Ospedaliera Spedali Civili Brescia Systemic treatment op:ons Somatosta:n analogues Interpheron
More informationAntiangiogenics are effective treatments in NETs
RENET: A randomized phase III trial comparing REgorafenib to placebo in patients with advanced, progressive, well-differentiated NEuroendocrine Tumors (NETs). Coordinators: Dr Julien Hadoux & Dr David
More informationNET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες
NETMASTERCLASS 2017: an interactive workshop NET ΠΝΕΥΜΟΝΑ: τι νεότερο / νέες μελέτες Νικόλαος Τσουκαλάς MD, MSc, PhD Ογκολόγος - Παθολόγος, MSc Βιοπληροφορική Επιμελητής Α, Ογκολογικό Τμήμα Νοσηλευτικό
More informationRecent developments of oncology in neuroendocrine tumors (NETs)
Recent developments of oncology in neuroendocrine tumors (NETs) Marc Peeters MD, PhD Coordinator Multidisciplinary Oncological Center Antwerpen (MOCA) Head of the Oncology Department UZA, Professor in
More informationSelection of Appropriate Treatment
Expert Review in Metastatic Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Selection of Appropriate Treatment Reference Slide Deck Neuroendocrine Tumors (NETs): A Diverse Group of Malignancies
More informationToward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives
Toward More Aggressive Management of Neuroendocrine Tumors: Current and Future Perspectives Moderator: Ashley Grossman, MD, FRCP Professor of Neuroendocrinology William Harvey Research Institute Barts
More informationAn Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT )
An Open-Label Phase Ib/II Study of Sulfatinib in Patients with Advanced Neuroendocrine Tumors (NCT02267967) J.M. Xu a, J. Li b, C.M. Bai c, N. Xu d, Z.W. Zhou e, Z.P. Li f, C.C. Zhou g, W. Wang h, J. Li
More informationNeuroendocrine Tumors: Just the Basics. George Fisher, MD PhD
Neuroendocrine Tumors: Just the Basics George Fisher, MD PhD Topics that we will not discuss Some types of lung cancer: Small cell neuroendocrine lung cancer Large cell neuroendocrine lung cancer Some
More informationGastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors
Gastrointestinal Neuroendocrine Tumors: A Closer Look at the Characteristics of These Diverse Tumors Jaume Capdevila, MD, PhD Vall d'hebron University Hospital Vall d'hebron Institute of Oncology (VHIO)
More informationPancreatic Neuroendocrine Tumours
UCLH Cancer Collaborative Pancreas Update Meeting 12 th July 2017 Pancreatic Neuroendocrine Tumours Dr. Christos Toumpanakis MD PhD FRCP Consultant in Gastroenterology/Neuroendocrine Tumours Hon. Senior
More informationNET und NEC. Endoscopic and oncologic therapy
NET und NEC Endoscopic and oncologic therapy Classification well-differentiated NET - G1 and G2 - carcinoid poorly-differentiated NEC - G3 - like SCLC well differentiated NET G3 -> elevated proliferation
More informationI nuovi farmaci: associazione o superamento del trattamento con analoghi
Milano, 20 giugno 2008 I NETs: a che punto siamo? I nuovi farmaci: associazione o superamento del trattamento con analoghi Nicola Fazio NET: possible targets for novel drugs Angiogenesis VEGF, EGF, IGF,
More informationTreatment algorithm Neuroendocrine tumours. Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece
Treatment algorithm Neuroendocrine tumours Gregory Kaltsas Endocrine Unit, Department of Pathophysiology, University of Athens, Greece Outline Presenting a meaningful algorithm Means used to develop algorithm
More informationPrognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas.
Prognostic factors and treatment of gastroenteropancreatic G3 neuroendocrine carcinomas. Halfdan Sorbye Medical Oncologist Professor, MD Dept of Oncology Haukeland Univ Hospital Bergen, Norway Gastroenteropancreatic
More informationTeresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal
Teresa Alonso Gordoa Servicio Oncología Médica Hospital Universitario Ramón y Cajal Incidence per 100,000 EPIDEMIOLOGY Incidence rates of neuroendocrine tumors by primary tumor site 1.4 1.2 1.0 0.8 0.6
More informationPancreatic NeuroEndocrine Tumors. Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium
Pancreatic NeuroEndocrine Tumors Prof Eric Van Cutsem, MD, PhD Gastroenterology/Digestive Oncology Leuven, Belgium Epidemiology Overall incidence 1.8 to 2.6 SEER, Europe Peak in 5 th and 6 th decade Incidence
More informationHot of the press. Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ
Hot of the press Γρηγόριος Καλτσάς MD FRCP Καθηγητής Παθολογίας Ενδοκρινολογίας ΕΚΠΑ Outline Diagnostic developments Histopathology Molecular Therapeutic developments Results on PRRT Telotristat in carcinoid
More informationEvaluation and Management of Neuroendocrine Tumors
Evaluation and Management of Neuroendocrine Tumors Jennifer Chan, MD, MPH Clinical Director, Program in Neuroendocrine and Carcinoid Tumors Dana-Farber/Brigham and Women's Cancer Center October 14, 2017
More informationThe PET-NET Study 2016 CNETS Grant Award
The PET-NET Study 2016 CNETS Grant Award CANM Meeting April 21, 2017 Hagen Kennecke, MD, MHA, FRCPC Medical Oncology, BC Cancer Agency Associate Professor, University of British Columbia Raja Ampat, Indonesia
More informationPANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION:
PANCREATIC NEUROENDOCRINE TUMORS DECEMBER 12, 2017 IF YOU EXPERIENCE TECHNICAL DIFFICULTY DURING THE PRESENTATION: CONTACT WEBEX TECHNICAL SUPPORT DIRECTLY AT: US TOLL FREE: 1-866-779-3239 TOLL ONLY: 1-408-435-7088
More informationSystematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors
At the Cutting Edge Received: February 29, 2016 Accepted: April 12, 2016 Published online: April 16, 2016 Systematic Review of the Role of Targeted Therapy in Metastatic Neuroendocrine Tumors Adrian Lee
More informationNICaN Pancreatic Neuroendocrine Tumour SACT protocols. 1.0 Dr M Eatock Final version issued
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Neuro-endocrine Tumours Dr Martin Eatock, Consultant Medical Oncologist & on behalf of the GI Oncologists Group,
More informationOPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS
OPTIMISING OUTCOMES IN GASTROINTESTINAL NEUROENDOCRINE TUMOURS Dr Mairéad McNamara Senior lecturer, University of Manchester & Honorary Consultant in Medical Oncology, The Christie NHS Foundation Trust
More informationOberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide)
GEP-NET Adel K. El-Naggar, M.D., Ph.D. The University of Texas MD Anderson Cancer Center, Houston, Texas Oberndofer 1907 Illeal Serotonin Secreting Tumor Carcinoid (Karzinoide) 1 Histogenesis 16 different
More informationA New Proposal for Metabolic Classification of NENs Stefano Severi IRST Meldola Italy
RADIONUCLIDE THERAPY AND ALLIED SCIENCE President: Giovanni Paganelli Chairman: Maria Salvato Baltimore USA Domenico Barone Meldola Italy A New Proposal for Metabolic Classification of NENs Stefano Severi
More informationCRITICAL ANALYSIS OF NEN GUIDELINES. G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines
CRITICAL ANALYSIS OF NEN GUIDELINES G Pentheroudakis Associate Professsor of Oncology Medical School, University of Ioannina Chair, ESMO Guidelines DISCLOSURES NO CONFLICTS OF INTEREST TO DECLARE UPDATED
More informationManagement of Neuroendocrine Tumors
Management of Neuroendocrine Tumors Professor Barbro Eriksson Department of Endocrine Oncology ENETS Centre of Excellence Uppsala University Hospital Diagnostic Challenges in NET Heterogeneous group of
More informationAn Immunotherapy Clinical Trial for NETs
An Immunotherapy Clinical Trial for NETs Pamela L. Kunz, MD Assistant Professor of Medicine / Oncology Stanford Cancer InsEtute March 1, 2015 Outline Clinical trial basics What have we learned from recent
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL NEUROENDOCRINE GASTRO-ENTERO-PANCREATIC TUMOURS GI Site Group Neuroendocrine gastro-entero-pancreatic tumours Authors: Dr.
More informationWhat the oncologist needs to know from the pathologist?
Grade 3 GEP Neuroendocrine Neoplasms: from pathology to the clinic and back What the oncologist needs to know from the pathologist? Marianne Pavel Friedrich Alexander Universität Erlangen-Nürnberg 30th
More informationOUTLINE. Background. What in NEC. What in NET G3. What in Minen/Manec. Future prospective. Conclusions
OUTLINE 1 2 3 4 5 6 Background What in NEC What in NET G3 What in Minen/Manec Future prospective Conclusions Median OS of poorly differentiated neuroendocrine carcinomas (NECs) The median survival for
More informationSIRT in the Management of Metastatic Neuroendocrine Tumors
SIRT in the Management of Metastatic Neuroendocrine Tumors Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director,
More informationPancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case
Case Report Pancreatic neuroendocrine cancer with liver metastases and multiple peritoneal metastases: report of one case Yang Wang, Dongbing Zhao Department of Abdominal Surgery, Cancer Institute & Hospital,
More informationWHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer
WHAT TO EXPECT IN 2015? - Renuka Iyer, MD Associate Professor of Medicine, University at Buffalo Associate Professor of Oncology, Roswell Park Cancer Institute Overview Diagnosis: Gallium scan Biomarkers
More informationOctreotide LAR in neuroendocrine tumours a summary of the experience
Endocrinology in oncology Review article Octreotide LAR in neuroendocrine tumours a summary of the experience Agnieszka Kolasińska-Ćwikła, MD, PhD Department of Chemotherapy, Oncology Clinic, Maria Sklodowska-Curie
More informationDevelopment of New Treatment Modalities Oncolytic Viruses and Nanotechnique
Development of New Treatment Modalities Oncolytic Viruses and Nanotechnique By Professor Kjell Öberg, M.D., Ph.D. Dept. of Endocrine Oncology, University Hospital, Uppsala, Sweden Nashville Oct. 2011 Hallmarks
More informationNovel Molecular Molecular Therapies In Hepatocarcinoma Prof Eric
Novel Molecular Therapies In Hepatocarcinoma Prof. Eric Raymond Department of Médical Oncology Hôpital Beaujon, Clichy Université Paris 7 Denis Diderot INSERM-U728 eric.raymond@bjn.aphp.fr HCC is a highly
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationGuideline A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO)
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Systemic Therapy of Incurable Gastroenteropancreatic Neuroendocrine Tumours S. Singh, D. Sivajohanathan, T.
More informationJon Trent, MD, PhD. Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center
Gastrointestinal Stromal Tumor GISTS 2010: After Standard of Care Jon Trent, MD, PhD Associate Professor Dept. of Sarcoma Medical Oncology The University of Texas, M. D. Anderson Cancer Center jtrent@mdanderson.org
More informationNew Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer
New Developments in the Care and Management of Patients with Gastroenteropancreatic Neuroendocrine Tumors Dr. Tim Asmis The Ottawa Hospital Cancer Centre MD, FRCPC CAGPO September 2018 Disclosures Consultant
More informationSUPPLEMENTARY INFORMATION
Supplementary Table 1. Therapies for non-men1 pancreatic neuroendocrine tumours (NETs) (published after 2011) Somatostatin analogues Tumour type a Intervention Number of participants/information available
More informationΧΗΜΕΙΟΘΕΡΑΠΕΙΑ ΣΤΑ ΝΕΤ: ΝΕΩΤΕΡΕΣ ΕΞΕΛΙΞΕΙΣ ΚΑΙ ΠΡΟΒΛΗΜΑΤΙΣΜΟΙ
ΧΗΜΕΙΟΘΕΡΑΠΕΙΑ ΣΤΑ ΝΕΤ: ΝΕΩΤΕΡΕΣ ΕΞΕΛΙΞΕΙΣ ΚΑΙ ΠΡΟΒΛΗΜΑΤΙΣΜΟΙ ΑΝΝΑ ΚΟΥΜΑΡΙΑΝΟΥ Ph.D ΔΙΕΥΘΥΝΤΡΙΑ ΕΣΥ, ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ ΑΙΜΑΤΟΛΟΓΙΚΗ-ΟΓΚΟΛΟΓΙΚΗ ΜΟΝΑΔΑ Δ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΠΑΘΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ
More informationThe role of multimodal treatment in patients with advanced lung neuroendocrine tumors
Review Article The role of multimodal treatment in patients with advanced lung neuroendocrine tumors Nicola Fazio 1 *, Antonio Ungaro 1, Francesca Spada 1 *, Chiara Alessandra Cella 1, Eleonora Pisa 2
More informationSystemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works.
Systemic Therapy for Pheos/Paras: Somatostatin analogues, small molecules, immunotherapy and other novel approaches in the works. Arturo Loaiza-Bonilla, MD, FACP Assistant Professor of Clinical Medicine
More informationEXOCRINE: 93% Acinar Cells Duct Cells. ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others
EXOCRINE: 93% Acinar Cells Duct Cells Digestive Enzymes Trypsin: Digests Proteins Lipases: Digests Fats Amylase: Digest Carbohydrates ENDOCRINE: 5% Alpha Cells Beta Cells Delta Cells Others Hormones Glucagon
More informationThe Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review
Gastrointestinal Cancer The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review MICHAEL MICHAEL, a ROCIO GARCIA-CARBONERO, b MATTHIAS M. WEBER, c CATHERINE
More informationLe target therapy nei Tumori Neuroendocrini
Le target therapy nei Tumori Neuroendocrini Take home messages Franco Grimaldi SOC Endocrinologia e Malattie del Metabolismo Nutrizione Clinica Azienda Ospedaliero-Universitaria Santa Maria della Misericordia
More informationRecent Advances in Gastrointestinal Cancers
Recent Advances in Gastrointestinal Cancers Ursina R. Teitelbaum, MD Section of Hematology/Oncology Abramson Cancer Center PENN 2016 Updates in Oncology June 23, 2016 none Disclosures ASCO 2016 Highlights:
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationGI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust
GI CARCINOID Dr Mussawar Iqbal Consultant Oncologist Hull and East Yorkshire Hospitals NHS Trust Introduction Carcinoid was old term, introduced in 1906 by German pathologist Cancinoma like More recent
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationMalignant pleural Mesothelioma: A Year In Review
Malignant pleural Mesothelioma: A Year In Review Rabab Gaafar,MD Prof. Medical Oncology NCI Cairo University National Cancer Institute Conference 2015 ASCO news in Mesothelioma Introduction ASCO news second
More informationNEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
NEUROENDOCRINE TUMOURS Updated December 2015 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Cynthia Card (Staff Medical Oncologist, University of Calgary)
More information12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval
12 AISF Special Conference Sorafenib: magnitude of benefit, side effects and stopping rules 9 years after approval ARMANDO SANTORO Roma 10-6-2016 SORAFENIB APPROVAL 29 OCTOBER 2007 Marketing authorization
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationRenal Cell Carcinoma: Systemic Therapy Progress and Promise
Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.
More informationReview Article Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature
Hindawi International Journal of Surgical Oncology Volume 2017, Article ID 6424812, 14 pages https://doi.org/10.1155/2017/6424812 Review Article Management Options for Advanced Low or Intermediate Grade
More informationDisclosure of Relevant Financial Relationships
Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS
More informationEverolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors
CHEST Original Research Everolimus Plus Octreotide Long-Acting Repeatable in Patients With Advanced Lung Neuroendocrine Tumors Analysis of the Phase 3, Randomized, Placebo-Controlled RADIANT-2 Study LUNG
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationLong Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationChair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Public slides Chair s presentation Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease 2 nd Appraisal Committee meeting Committee
More informationNeuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC
Neuroendocrine Tumours If you don t suspect it you can t detect it! Dr JWS Devar HPB Surgeon University of Witwatersrand E-AHPBA CHBAH & WDGMC Case Study 43 yr old female with a history of a left mastectomy
More informationNew Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain
New Therapies in HCC Bruno Sangro Clínica Universidad de Navarra. IdISNA. CIBERehd. Pamplona, Spain PHC 2018 - www.aphc.info EASL-EORTC Guidelines EASL EORTC Guidelines. J Hepatol. 2012;56:908-43. Systemic
More informationEmbolotherapy for Cholangiocarcinoma: 2016 Update
Embolotherapy for Cholangiocarcinoma: 2016 Update Igor Lobko,MD Chief, Division Vascular and Interventional Radiology Long Island Jewish Medical Center GEST 2016 Igor Lobko, M.D. No relevant financial
More informationThe Current Champion: Angiogenesis inhibitors
The Current Champion: Angiogenesis inhibitors Baek-Yeol RYOO University of Ulsan College of Medicine ASAN Medical Center Dept. of Oncology Seoul, Korea Survival probability Sorafenib: Overall Survival
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Raymond E, Dahan L, Raoul J-L, et al. Sunitinib malate for the treatment
More informationUpdate on the Management of HER2+ Breast Cancer. Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany
Update on the Management of HER2+ Breast Cancer Christian Jackisch, MD, PhD Sana Klinikum Offenbach Offenbach, Germany Outline Treatment strategies for HER2-positive metastatic breast cancer since First
More informationRIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO. Dra. Elena Aguirre H.U. Miguel Servet
RIBOCICLIB EN PRIMERA LINEA DE TRATAMIENTO Dra. Elena Aguirre H.U. Miguel Servet INTRODUCTION ADVANCED BREAST CANCER HR+/HER2- YES Consider Chemo VISCERAL CRISIS? NO Endocrine Therapy X3 Toxicity Progresive
More informationAdjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial
Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Xin Huang 1 and Qiang (Casey) Xu 2 1 Pfizer Oncology
More informationNeuroendocrine Tumors
Carcinoid tumours: origin Neuroendocrine Tumors THE A, B,C s Bronchopulmonary system Other 8% 28% Carcinoid site Digestive system 64% 2.3 28 28.5 Other Colon and rectum Small intestine Colon, except appendix
More informationPNET 3/7/2015. GI and Pancreatic NETs. The Postgraduate Course in Breast and Endocrine Surgery. Decision Tree. GI and Pancreatic NETs.
GI and Pancreatic NETs The Postgraduate Course in Breast and Endocrine Surgery Disclosures Ipsen NET Advisory Board Marines Memorial Club and Hotel San Francisco, CA Eric K Nakakura San Francisco, CA March
More informationInnovaciones en el tratamiento del ca ncer renal. Enrique Grande
Innovaciones en el tratamiento del ca ncer renal Enrique Grande The enriched inflammatory environment of RCC Chen Z, et al. Nat Rev Cancer 2014 Available agents are expanding across the three eras of arcc
More informationPage. Objectives: Hormone Therapy Resistance: Challenges and Opportunities. Research Support From Merck
Hormone Therapy Resistance: Challenges and Opportunities Pamela. N. Munster, MD University of California, San Francisco Financial Disclosures Research Support From Merck Objectives: Understanding the current
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationHorizon Scanning in Oncology
Horizon Scanning in Oncology Everolimus (Afinitor ) for the treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin DSD: Horizon Scanning in Oncology Nr. 024 ISSN online 2076-5940
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012
pan-canadian Oncology Drug Review Final Clinical Guidance Report Sunitinib malate (Sutent) for pancreatic neuroendocrine tumours May 3, 2012 DISCLAIMER Not a Substitute for Professional Advice This report
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationBreast cancer update. Iryna Kuchuk, MD Oncology department Meir Medical Center
Breast cancer update Iryna Kuchuk, MD Oncology department Meir Medical Center Overview Cancer Death Rates* Among Women, US,1930-2009 Factors Associated with Reduction In Breast Cancer Mortality Early
More informationIII Sessione I risultati clinici
10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it
More informationSystemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid
Systemic Therapy for Gastroenteropancreatic (GEP) Neuroendocrine Tumors and Lung Carcinoid The Medical Oncology Perspective Nevena Damjanov, MD Associate professor Abramson Cancer Center of the University
More informationTumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016
1 Tumor Growth Rate (TGR) A New Indicator of Antitumor Activity in NETS? IPSEN NET Masterclass Athens, 12 th November 2016 Philippe RUSZNIEWSKI ENETS Centre of Excellence, Beaujon Hospital, Clichy, France
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationOutline of the presentation
Outline of the presentation Breast cancer subtypes and classification Clinical need in estrogen-positive (ER+) metastatic breast cancer (mbc) Sulforaphane and SFX-01: the preclinical evidence STEM Phase
More informationProstate cancer Management of metastatic castration sensitive cancer
18 th Annual Advances in Oncology - 2017 Prostate cancer Management of metastatic castration sensitive cancer Urothelial carcinoma Non-muscle invasive urothelial carcinoma Updates in metastatic urothelial
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationUpdates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010
HIGHLIGHT ARTICLE Updates in Pancreatic Neuroendocrine Carcinoma Highlights from the 2010 ASCO Annual Meeting. Chicago, IL, USA. June 4-8, 2010 Susan Alsamarai 1, Steven K Libutti 2, Muhammad Wasif Saif
More information